Mark Fleming, MD, DPhil
|Academic Title||S. Burt Wolbach Professor of Pathology|
300 Longwood Avenue
Boston MA 02115
Mark Fleming's research is focused on determining how erythroid cells acquire and utilize iron. Researchers in his lab are pursuing two general approaches:
- Postionally cloning and characterizing the genes underlying several mouse hereditary defects in erythroid iron metabolism.
- Using targeted mutagenesis in the mouse to study proteins implicated in the pathogenesis in a group of bone marrow disorders known as sideroblastic anemias. In those disorders, erythroid precursors develop pathologic iron deposits in mitochondria, which play a unique role in metabolizing iron and heme. He is seeking to characterize proteins responsible for mitochondrial iron import and utilization.
About Mark Fleming
Mark Fleming earned his undergraduate degree in molecular biology from Princeton University in 1987, his doctor of philosophy degree in organic chemistry from the University of Oxford in England in 1990 and his medical degree from Harvard Medical School in 1993.
Dr. Fleming did his residency in anatomic pathology and fellowship in hematopathology at Brigham and Women's Hospital. He also did a postdoctoral fellowship in the Division of Hematology/Oncology here at Children's. Dr. Fleming was named a Pew Fellow in Biomedical Research
- Fleming, MD. The genetics of inherited sideroblastic anemias. Seminars in Hematology 2002; 39: 270-281.
- Fleming MD, Campagna DR, Haslett JN, Trenor CC 3rd, Andrews NC. A mutation in a mitochondrial transmembrane protein is responsible for the pleiotropic hematological and skeletal phenotype of flexed-tail (f/f) mice. Genes & Development 2001; 15: 652-657.
- Fleming MD, Trenor CC, Su M, Foernzler D, Beier D, Dietrich W, and Andrews NC. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nature Genetics 1997; 16: 383-386.